This Phase 2 clinical research study is evaluating the safety and effectiveness of a once-daily oral investigational medicine that may improve anemia and reduce the need for red blood cell (RBC) transfusions among some patients who are chronically transfused.
Individuals with beta thalassemia that is treated with regular transfusions, and who are between the ages of 18 and 40 years old, may be able to participate.
Dr. Chou's research laboratory focuses on regenerative blood cellular therapy, the mechanisms of normal human hematopoietic development, and how these become disrupted in hematologic diseases.
Infants and children who undergo heart surgery are better off receiving fresh whole blood transfusions from a single donor, compared to receiving component blood from multiple donors, according to new research from The Children’s Hospital of Philadelphia.
